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Bioinformatics for Human Proteomics: 
Current State and Future Status 
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Exactly 10 years ago, at the 4th 
Siena meeting, we proposed to 
annotate in Swiss-Prot all the 
human proteins 
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A „complete‟ set of annotated 
human proteins 
• In September 2008, we had annotated 20’330 human 
protein entries in UniProtKB/Swiss-Prot; 
• They originate from about 20’400 protein-coding 
genes; 
• Why „about‟? 
– There are sets of genes that encode for identical proteins 
(example: 14 genes code for histone H4); 
– There are genes that codes for two or more proteins that 
have nothing in common in term of their sequence 
(bicistronic or alternative splicing); 
– There are some other weird cases! 
• The precise definition of what is a gene is dependent 
on who is using/making that definition. 
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Since... 
• Since the beginning of 2009, we have 
added 130 «new» sequences, but we 
have «deleted» 171 proteins; 
• Our gut feeling is that we are slowly but 
inexorably creeping toward slightly under 
20‟000 human-protein coding genes. 
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Alternative isoforms 
• Produced by alternative splicing, promoter usage or initiation; 
• Currently we have 14’700 additional isoforms in about 7’600 
entries; 
• This means that 38% of the protein-coding genes are already 
annotated to code for at least 2 different protein sequences; 
• We estimate (based on an in-depth analysis of genes encoded 
on chromosome 13) that this number will rise above 60% and 
the average number of isoforms to 3; 
• This mean that we can already estimate that there is probably 
about 50’000 different human proteins that are produced by as 
many (or even more) transcripts.  
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Sequence variants 
• We have information concerning about 63’000 SAP 
(single amino-acid polymorphisms); 
• 20’000 are linked to diseases. This information is 
mined from the literature and from disease-specific 
databases; 
• This means that, excluding disease variants, there is 
already an average of 2 SAPs per protein; 
• The „non-disease‟ variants are obtained from a 
variety of sources (HAPMAP, NIEHS-SNPs, etc); 
• They will increasingly come from whole human 
genome sequencing efforts (1‟000 genomes, etc). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
10
.5
05
0.
1 
: P
os
te
d 
20
 O
ct
 2
01
0
Caveat about variants 
• The canonical human genome sequence is artefactual. 
There is no such thing as an average genome; 
• Some reported variants represent in fact the «majority» 
sequence; 
• In humans, variability at level of proteins is not restricted to 
SAPs, one needs also to take into account: 
– Segregating pseudogenes (example: olfactory 
receptors); 
– Copy number variation; 
– Active retrotransposable elements (LINE-1, ERVs); 
• The solution:to gradually move to what microbiologists 
have already embraced: a pangenome. 
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Post-translational modifications 
• We have about 80’000 annotated PTMs; 
• Only half of them have been experimentally 
obtained; 
• The rest are predicted or inferred from experiments 
done in other species; 
• We are just looking at the tip of the iceberg. But 
proteomics studies are starting to address this issue 
seriously; 
• If we make a very modest estimate of 5 different 
PTMs per protein and that they may be 
independently regulated, you already get a 100x 
increase in the number of protein species in our 
body (to a total of 5 million).  
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The PTM world is still largely uncharted 
(3R)-3-hydroxyasparagine, (3R)-3-hydroxyaspartate, (3S)-3-hydroxyasparagine, 1'-histidyl-3'-tyrosine, 1-
thioglycine, 2',4',5'-topaquinone, 2,3-didehydroalanine, 3'-(S-cysteinyl)-tyrosine, 3-hydroxyproline, 3-
oxoalanine, 4-amino-3-isothiazolidinone serine, 4-carboxyglutamate, 4-hydroxyproline, 5-glutamyl, 5-
glutamyl glycerylphosphorylethanolamine, 5-hydroxylysine, 5-imidazolinone, ADP-ribosylasparagine, 
ADP-ribosylcysteine, ADP-ribosylserine, Allysine, Arginine amide, Asparagine amide, Aspartate 1-
(chondroitin 4-sulfate)-ester, Asymmetric dimethylarginine, Beta-decarboxylated aspartate, Cholesterol 
glycine ester, Citrulline, Cysteine methyl ester, Cysteine sulfenic acid, Cysteinyl-selenocysteine, 
Deamidated asparagine, Deamidated glutamine, Dimethylated arginine, Diphthamide, Disulfide bond, 
GPI-anchor amidated alanine, GPI-anchor amidated asparagine, GPI-anchor amidated aspartate, GPI-
anchor amidated cysteine, GPI-anchor amidated glycine, GPI-anchor amidated serine, Glutamic acid 1-
amide, Glutamine amide, Glycine amide, Glycyl adenylate, Glycyl lysine isopeptide, Hydroxyproline, 
Hydroxyproline, Hypusine, Isoglutamyl cysteine thioester, Isoglutamyl lysine isopeptide, Isoleucine amide, 
Leucine amide, Leucine methyl ester, Lysine amide, Lysine tyrosylquinone, Methionine amide, N,N,N-
trimethylalanine, N-acetylalanine, N-acetylaspartate, N-acetylcysteine, N-acetylglutamate, N-
acetylglycine, N-acetylmethionine, N-acetylproline, N-acetylserine, N-acetylthreonine, N-acetylvaline, N-
myristoyl glycine, N-palmitoyl cysteine, N-palmitoyl glycine, N-pyruvate 2-iminyl-valine, N4,N4-
dimethylasparagine, N6,N6,N6-trimethyllysine, N6,N6-dimethyllysine, N6-(pyridoxal phosphate)lysine, N6-
(retinylidene)lysine, N6-1-carboxyethyl lysine, N6-acetyllysine, N6-biotinyllysine, N6-carboxylysine, N6-
lipoyllysine, N6-methylated lysine, N6-methyllysine, N6-myristoyl lysine, Nitrated tyrosine, O-(pantetheine 
4'-phosphoryl)serine, O-AMP-threonine, O-AMP-tyrosine, O-acetylserine, O-acetylthreonine, O-decanoyl 
serine, O-palmitoyl serine, Omega-N-methylarginine, Omega-N-methylated arginine, Omega-
hydroxyceramide glutamate ester, Phenylalanine amide, Phosphatidylethanolamine amidated glycine, 
Phosphohistidine, Phosphoserine, Phosphothreonine, Phosphotyrosine, PolyADP-ribosyl glutamic acid, 
Proline amide, Pyrrolidone carboxylic acid, Pyruvic acid, S-(dipyrrolylmethanemethyl)cysteine, S-8alpha-
FAD cysteine, S-Lysyl-methionine sulfilimine, S-cysteinyl cysteine, S-farnesyl cysteine, S-geranylgeranyl 
cysteine, S-glutathionyl cysteine, S-methylcysteine, S-nitrosocysteine, S-palmitoyl cysteine, S-stearoyl 
cysteine, Sulfoserine, Sulfotyrosine, Symmetric dimethylarginine, Tele-8alpha-FAD histidine, Tele-
methylhistidine, Thyroxine, Triiodothyronine, Tyrosine amide, Valine amide 
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From genome to proteome 
post-translational 
modifications of proteins 
(PTMs) 
50-100 fold increase  
alternative splicing 
of mRNA 
2-5 fold increase  
~ 50 to 100’000 
transcripts 
(mRNAs) 
~ 20’000 protein 
coding-genes 
~ 5'000'000 
different 
proteins 
 
Protein complexity 
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Breakdown in term of Protein 
Evidence (PE) of human proteins 
• 1: Evidence at protein level     13340 (65.8%) 
• 2: Evidence at transcript level   6018 (29.7%) 
• 3: Inferred from homology           210 (  1.0%) 
• 4: Predicted                                 97 (  0.5%) 
• 5: Uncertain                                 600 (  2.9%) 
But even for the 66% where there is evidence, at protein level, 
of the protein existence, there is still a lots to be done at the 
proteomic level (PTMs, interactions, subcellular location, 
tissue-specificity, etc). 
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Characterization status of human proteins
Maybe
Potentially
Putative
Expected
Probably
Hopefully
In the framework of the annotation effort to 
produce a complete set of human entries, we were 
confronted by how little is known on the function of 
many human proteins…. 
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Computer Analysis and Laboratory 
Investigation of Proteins of Human Origin 
A new group of the University of Geneva and the Swiss Institute of 
Bioinformatics 
Directed by Amos Bairoch and Lydie Lane 
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The 3 missions of CALIPHO 
• Carry out laboratory experiments on 
selected sets of uncharacterized human 
proteins to discover their function; 
• Develop neXtProt, an ambitious new 
knowledge resource centered around 
human proteins; 
• Organize a collective effort that pools 
resources around the world with the goal of 
functionally characterize all human proteins. 
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• What: a comprehensive resource that complements 
SIB/EBI Swiss-Prot human protein annotation efforts. 
neXtProt is expected to become the central resource 
of human protein-centric information; 
• How:  
– by mining, in the most appropriate way and with our 
stringent quality criteria, many external data resources.  
 In this context we plan to add additional protein/protein and 
protein/small molecules interactions, proteomics data, 
pathway information, tissular and cellular expression from 
antibodies, variation data (such as SNP frequencies), siRNA 
screen data, microRNA targets, microarray expression data, 
phylogenetic profiling, etc; 
– by integrating experimental results from an extensive 
network of collaborating laboratories. 
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2D-gel databases  
ANU-2DPAGE 
Aarhus/Ghent-2DPAGE 
Cornea-2DPAGE  
DOSAC-COBS-2DPAGE 
HSC-2DPAGE 
OGP 
PMMA-2DPAGE 
REPRODUCTION-2DPAGE 
SWISS-2DPAGE 
World-2DPAGE 
Family and domain 
databases 
Gene3D 
InterPro 
PANTHER 
PIRSF 
Pfam 
PRINTS 
ProDom 
PROSITE 
SMART 
TIGRFAMs 
Organism-specific 
databases 
GeneCards 
H-InvDB  
HGNC 
MIM 
Orphanet  
PharmGKB 
Enzyme and pathway 
databases 
BioCyc 
BRENDA 
Pathway_Interaction_DB 
Reactome 
Miscellaneous 
ArrayExpress 
Bgee  
BindingDB 
CleanEx 
dbSNP 
DIP 
DrugBank  
GO 
HOGENOM 
HOVERGEN 
IntAct 
LinkHub 
NextBio  
Protein family/group 
databases 
GermOnline 
MEROPS 
PeroxiBase 
REBASE 
TCDB  
Sequence databases 
EMBL 
IPI 
PIR 
RefSeq 
UniGene 
3D structure 
databases 
DisProt 
HSSP 
PDB 
PDBsum 
SMR 
PTM databases 
GlycoSuiteDB 
PhosphoSite 
UniProtKB/Swiss-Prot 
Human entries links 
Genome annotation 
databases 
Ensembl 
GeneID  
KEGG 
NMPDR 
Proteomics 
HPA 
PeptideAtlas 
PRIDE 
In Swiss-Prot users always need to navigate 
toward many external resources so as to 
consolidate data into knowledge  
In neXtProt the most pertinent data will be 
integrated so as to enable complex queries   
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What is not neXtProt? 
• neXtProt is not Swiss-Prot “Plus”; 
• Yes, neXtProt will contains a wealth of 
data not available in Swiss-Prot; 
• But the real challenge is to build a real 
knowledge platform where our users can 
ask meaningful questions and hopefully 
obtain the answers that they seek! 
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When and what 
• We will have a first public version out in October 2010 
• In terms of data, it will contains: 
– All of Swiss-Prot human data: sequences and annotations; 
– Human Proteome Atlas organ and tissue expression 
information from antibodies; 
– Metadata on mRNA expression from microarrays and ESTs 
from Bgee (analyzed from ArrayExpress and UniGene); 
– Additional SNPs from dbSNP and Ensembl; 
– Chromosomal location and exons mapping from Ensembl; 
– Affymetrix and Illumina chip sets identifiers. 
• In terms of interface, it will offers: 
– An intuitive query interface; 
– Different specialized views (function, medical, expression, 
etc.); 
– The possibility to tag and label proteins. 
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A variety of views 
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The future 
• Our vision is to gradually build up neXtProt, 
not only by adding new data resources but: 
– By integrating state of the art data mining tools; 
– By integrating some forms of “social networking” 
functionalities allowing researches to share 
ideas and data; 
– By enabling the modeling of hypothesis inside 
the framework of the platform. 
• To work closely with HUPO HPP 
stakeholders to define what proteomics-
derived data we will represent in neXtProt. 
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A prototype of a future proteomics view 
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You can already start 
test drive neXtProt in 
a few days 
Just go to 
beta.nextprot.org 
and sign up  
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CALIPHO@UniGe_and_SIB 
• neXtProt content:  
– Coordinator: Pascale Gaudet 
– Biocurators: Guislaine Argoud-Puy, Isabelle Cusin, Paula 
Duek 
• neXtProt software developers:  
– Olivier Evalet, Alain Gateau, Anne Gleizes, Catherine 
Zwahlen and Alexandre Masselot (GeneBio) 
• Bioinformatics research:  
– Anais Mottaz, Anne-Lise Veuthey (Swiss-Prot), Marco 
Pagni (VitalIT) 
• Laboratory research:  
– Franck Bontems, Marjorie Desmurs, Camille Mary, 
Fabiana Tirone, Rachel Porcelli, Irene Rossito and Lisa 
Salleron 
• Directed by:  
– Amos Bairoch, Lydie Lane and Nasri Nahas 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
10
.5
05
0.
1 
: P
os
te
d 
20
 O
ct
 2
01
0
The CALIPHO group 
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